RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q3 2020
Top Holdings70 positions
ASCENDIS PHARMA A/S | 5.9M | $912M | 16.7% | $83.05 | +83.34% | 8 qtrssince 2018-Q4 | Increased 74 |
FORMA THERAPEUTICS HLDGS INC | 9M | $449.1M | 8.2% | — | — | 2 qtrssince 2020-Q2 | Unchanged 0 |
| 4.8M | $264.5M | 4.8% | — | — | 4 qtrssince 2019-Q4 | Unchanged 0 | |
VAXCYTE INC | 5.3M | $260.9M | 4.8% | $31.20 | +65.06% | 2 qtrssince 2020-Q2 | Decreased 0 |
TG Therapeutics Inc | 8.8M | $236.2M | 4.3% | $8.58 | +204.86% | 8 qtrssince 2018-Q4 | Decreased 0 |
NKARTA INC COM | 5.6M | $168.5M | 3.1% | $30.36 | 0.00% | 1 qtr | New 84 |
AXSOME THERAPEUTICS INC | 2M | $145M | 2.7% | $50.95 | +41.85% | 7 qtrssince 2019-Q1 | Unchanged 0 |
PHATHOM PHARMACEUTICALS INC | 3.8M | $140.3M | 2.6% | $32.43 | +10.36% | 4 qtrssince 2019-Q4 | Unchanged 0 |
SERES THERAPEUTICS INC | 4.8M | $134.5M | 2.5% | — | — | — | New 78 |
NOVAVAX INC COM NEW | 1.2M | $129.9M | 2.4% | $83.61 | +29.11% | 2 qtrssince 2020-Q2 | Decreased 0 |
89BIO INC | 4.7M | $121.5M | 2.2% | — | — | 4 qtrssince 2019-Q4 | Increased 71 |
RHYTHM PHARMACEUTICALS INC | 5.1M | $111.4M | 2.0% | $23.93 | -9.46% | 8 qtrssince 2018-Q4 | Decreased 0 |
MACROGENICS INC COM | 4.4M | $110.2M | 2.0% | $28.28 | -10.93% | 2 qtrssince 2020-Q2 | Decreased 0 |
EIDOS THERAPEUTICS INC | 2.2M | $109.3M | 2.0% | — | — | 8 qtrssince 2018-Q4 | Increased 47 |
ITEOS THERAPEUTICS INC | 4.4M | $109M | 2.0% | — | — | 1 qtr | New 69 |
ZOGENIX INC | 5.5M | $98.4M | 1.8% | — | — | 8 qtrssince 2018-Q4 | Increased 65 |
ADVERUM BIOTECHNOLOGIES INC | 9.4M | $96.9M | 1.8% | — | — | — | Increased 56 |
ADAPTIMMUNE THERAPEUTICS PLC Spon ADS Each Rep 6 Ord Shs | 11.3M | $90.4M | 1.7% | $3.01 | +154.84% | 3 qtrssince 2020-Q1 | Decreased 0 |
Defiance Trillion Dollar Club I | 6.2M | $87.6M | 1.6% | — | — | 3 qtrssince 2020-Q1 | Unchanged 0 |
ARVINAS INC COM | 3.7M | $86.7M | 1.6% | $29.09 | -19.18% | 8 qtrssince 2018-Q4 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $5.5B across 70 positions as of Q3 2020. Top holdings: ASND (16.7%), FMTX (8.2%), CHEMOCENTRYX INC (4.8%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
Active quarter - 18 new positions, 5 exits, 7 increased. Top move: NKTX (NEW, conviction 84). Portfolio: $5.5B across 70 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR